학술논문
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)
Document Type
article
Author
Cloughesy, Timothy F; Brenner, Andrew; de Groot, John F; Butowski, Nicholas A; Zach, Leor; Campian, Jian L; Ellingson, Benjamin M; Freedman, Laurence S; Cohen, Yael C; Lowenton-Spier, Noa; Minei, Tamar Rachmilewitz; Shmueli, Shifra Fain; Avgeropoulos, Nicholas; Beck, Joseph; Benkers, Tara; Bokstein, Felix; Burton, Eric; Butowski, Nicholas; Campian, Jian; Carrillo, Jose; Cloughesy, Timothy; de Groot, John; De Robles, Paula; Drappatz, Jan; Dunbar, Irine; Fink, Karen; Groves, Morris; Han, Xiaosi; Adila, Hormigo; Jensen, Randy; Kowalska, Agnieszka; Kumthekar, Pyriya; Lee, Mijung; Lesser, Glenn; Lossos, Alexander; Lukas, Rimas; Macdonald, David; Mammoser, Aaron; Mechtler, Laszlo; Mohile, Nimish; Nagpal, Seema; Nicholas, Garth; Kreisl, Teri; Pan, Edward; Peak, Scott; Pearlman, Michael; Perry, James; Peterson, Richard; Piccioni, David; Robins, Henry; Ronan, Lara; Salacz, Michael; Schiff, David; Tran, David; Tzuk-Shina, Tzahala; Walbert, Tobias; Wen, Patrick; Youst, Shlomit; Y, Wen Patrick
Source
Neuro-Oncology. 22(5)
Subject
Language
Abstract
BackgroundOfranergene obadenovec (VB-111) is an anticancer viral therapy that demonstrated in a phase II study a survival benefit for patients with recurrent glioblastoma (rGBM) who were primed with VB-111 monotherapy that was continued after progression with concomitant bevacizumab.MethodsThis pivotal phase III randomized, controlled trial compared the efficacy and safety of upfront combination of VB-111 and bevacizumab versus bevacizumab monotherapy. Patients were randomized 1:1 to receive VB-111 1013 viral particles every 8 weeks in combination with bevacizumab 10 mg/kg every 2 weeks (combination arm) or bevacizumab monotherapy (control arm). The primary endpoint was overall survival (OS), and secondary endpoints were objective response rate (ORR) by Response Assessment in Neuro-Oncology (RANO) criteria and progression-free survival (PFS).ResultsEnrolled were 256 patients at 57 sites. Median exposure to VB-111 was 4 months. The study did not meet its primary or secondary goals. Median OS was 6.8 versus 7.9 months in the combination versus control arm (hazard ratio, 1.20; 95% CI: 0.91-1.59; P = 0.19) and ORR was 27.3% versus 21.9% (P = 0.26). A higher rate of grades 3-5 adverse events was reported in the combination arm (67% vs 40%), mainly attributed to a higher rate of CNS and flu-like/fever events. Trends for improved survival with combination treatment were seen in the subgroup of patients with smaller tumors and in patients who had a posttreatment febrile reaction.ConclusionsIn this study, upfront concomitant administration of VB-111 and bevacizumab failed to improve outcomes in rGBM. Change of treatment regimen, with the lack of VB-111 monotherapy priming, may explain the differences from the favorable phase II results.Clinical trials registrationNCT02511405.